AVROBIO logo
AVROBIO AVRO

Quarterly report 2025-Q3
added 11-06-2025

report update icon

AVROBIO Income Statement 2011-2026 | AVRO

Annual Income Statement AVROBIO

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

56.3 M 54.7 M 62.1 K 522 M 566 M 174 M - - - - - - -

Shares

44.3 M 43.7 M 42.9 K 36.4 M 27.4 M 13.4 M - - - - - - -

Historical Prices

1.27 1.25 1.45 11 19.3 16.7 - - - - - - -

Net Income

12.2 M -106 M -119 M -120 M -73 M -46.4 M -18.6 M -4.66 M - - - - -

Operating Income

10.2 M -105 M -119 M -120 M -75.8 M -46.2 M -18.4 M - - - - - -

EBITDA

10.8 M -104 M -117 M -119 M -75 M -45.9 M -18 M -4.59 M - - - - -

Operating Expenses

71.7 M 105 M 119 M 120 M 75.8 M 46.2 M - - - - - - -

General and Administrative Expenses

24 M 33.2 M 35.7 M 33 M 20.8 M 11.1 M 3.2 M 1.96 M - - - - -

All numbers in USD currency

Quarterly Income Statement AVROBIO

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

18.7 M 18.7 M 17.2 M 14.9 M 14.7 M 2.92 M 1.39 M 2.63 M 1.32 M 1.23 M 44 M 43.9 M 43.8 M 43.7 M 43.7 K 43.7 M 43.6 K 42.5 K 41.6 M 43.7 M 36.4 M 36.1 M 33.7 M 31.6 M 30.3 M 24 M 23.9 M 23.8 M 23.7 M 3.53 M 2.32 M 2.31 M 2.26 M 2.2 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-19 M -20 M -15.9 M - -17.7 M -12.7 M -15.2 M - -10.1 M -10.5 M -25 M - -23 M -28.1 M -29.8 M - -32.6 M -31.4 M -26.9 M - -36.8 M -28.8 M -26 M - -17.1 M -16.1 M -17.1 M - -11.6 M -10.5 M -8.24 M - -6.44 M -2.53 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-21.9 M -22.3 M -18.3 M - -19.6 M -11.4 M -13 M - -10.1 M -10.6 M -25.2 M - -23 M -27.8 M -29.4 M - -32.6 M -31.4 M -26.9 M - -36.7 M -28.9 M -26.6 M - -18.1 M -16.6 M -17.7 M - -12.2 M -9.55 M -7.79 M - -6.37 M -2.54 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-31 K -48 K -32 K - -7 K -5 K -403 K - -1 K -8 K 15 K - -95 K 5 K -45 K - 5 K -21 K - - -74 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -17.9 M - -19.4 M -11.2 M -12.6 M - -9.86 M -10.4 M -24.9 M - -22.6 M -27.4 M -29 M - -32.2 M -31.1 M -26.6 M - -36.4 M -28.6 M -26.3 M - -17.8 M -16.2 M -17.5 M - -12 M -9.48 M -7.77 M - -6.34 M -2.53 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

21.9 M 22.3 M 18.3 M - 19.6 M 11.4 M 13 M - 10.1 M 10.6 M 25.2 M - 23 M 27.8 M 29.4 M - 32.6 M 31.4 M 26.9 M - 36.7 M 28.9 M 26.6 M - 18.1 M 16.6 M 17.7 M - 12.2 M 9.55 M 7.79 M - 6.37 M 2.54 M - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.96 M 5.15 M 5.26 M - 5.32 M 4.35 M 2.15 M - 1.98 M 1.86 M 7.89 M - 7.07 M 8.9 M 10.2 M - 9.58 M 8.83 M 8.36 M - 8.21 M 7.99 M 8.32 M - 5.02 M 4.34 M 5.25 M - 3 M 2.14 M 2.14 M - 959 K 661 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company AVROBIO (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.13 0.55 % $ 651 M usaUSA
Exelixis Exelixis
EXEL
$ 48.2 8.51 % $ 13.1 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.53 2.85 % $ 70.6 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 28.81 1.48 % $ 2.69 B belgiumBelgium
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.95 1.5 % $ 17.2 B danmarkDanmark
Genprex Genprex
GNPX
$ 0.91 2.24 % $ 849 K usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.4 1.63 % $ 6.83 B spainSpain
InflaRx N.V. InflaRx N.V.
IFRX
$ 2.51 27.16 % $ 152 M germanyGermany
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 77.0 2.33 % $ 12.3 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 94.64 -0.9 % $ 27.2 B germanyGermany
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.29 0.91 % $ 260 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 85.79 3.72 % $ 7.25 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 13.58 0.97 % $ 1.8 B australiaAustralia
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 231.58 -0.31 % $ 4.24 B usaUSA
INmune Bio INmune Bio
INMB
$ 1.54 - $ 38.1 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 41.64 3.75 % $ 3.58 B usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.58 1.03 % $ 3.74 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 107.36 1.46 % $ 5.39 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
$ 3.61 26.17 % $ 1.1 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.46 -1.14 % $ 5.7 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.0 2.46 % $ 3.05 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 41.6 19.64 % $ 286 B franceFrance
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA